# Myositis Interstitial Lung Disease Nintedanib Trial

> **NCT05799755** · PHASE4 · COMPLETED · sponsor: **Rohit Aggarwal, MD** · enrollment: 49 (actual)

## Conditions studied

- Myositis Associated Interstitial Lund Disease (MA-ILD)

## Interventions

- **DRUG:** Nintedanib
- **DRUG:** Placebo
- **DRUG:** Standard of Care

## Key facts

- **NCT ID:** NCT05799755
- **Lead sponsor:** Rohit Aggarwal, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-01
- **Primary completion:** 2025-03-17
- **Final completion:** 2025-12-31
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2026-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05799755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05799755, "Myositis Interstitial Lung Disease Nintedanib Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05799755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*